KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Assets (2016 - 2025)

BeOne Medicines (ONC) has disclosed Assets for 11 consecutive years, with $6.3 billion as the latest value for Q2 2025.

  • On a quarterly basis, Assets changed N/A to $6.3 billion in Q2 2025 year-over-year; TTM through Jun 2025 was $6.3 billion, a N/A change, with the full-year FY2024 number at $5.9 billion, up 22.93% from a year prior.
  • Assets was $6.3 billion for Q2 2025 at BeOne Medicines, up from $5.9 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $8.5 billion in Q4 2021 to a low of $4.8 billion in Q4 2023.
  • A 5-year average of $6.1 billion and a median of $5.7 billion in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: surged 52.4% in 2021, then plummeted 35.78% in 2022.
  • BeOne Medicines' Assets stood at $8.5 billion in 2021, then plummeted by 35.78% to $5.5 billion in 2022, then dropped by 12.13% to $4.8 billion in 2023, then increased by 22.93% to $5.9 billion in 2024, then increased by 6.38% to $6.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Assets are $6.3 billion (Q2 2025), $5.9 billion (Q4 2024), and $5.7 billion (Q1 2024).